MedTrace Logo

Study on Efficacy and Safety of Human Albumin in Burn Shock Recovery

NCT04928859 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 364

Last updated 2021-06-16

No results posted yet for this study

Summary

To explore the effects and safety of human albumin in burn shock recovery, and then provide a theoretical basis for its rational use.

Conditions

  • Burns Shock

Interventions

DRUG

Albumin

At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group. The patients who have no albumin use during their hospitalization in the burn ward consisted the control group.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Hai-Bin Dai, doctor · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-01
Primary Completion
2019-01-01
Completion
2020-07-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04928859 on ClinicalTrials.gov